InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,307.88
(
0.48%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.70
(
0.33%
)
Bitcoin
61,448.38
(
-0.26%
)
Post# of 426266
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biowreck

Send PM Follow Ignore
Followers 7
Posts 564
Boards Moderated 0
Alias Born 08/27/2014

biowreck

Re: massulo52 post# 164989

Tuesday, 12/04/2018 9:44:06 AM

Tuesday, December 04, 2018 9:44:06 AM

Post# of 426266
The key issue is whether or not payers will readily cover Vascepa as an add-on to statin therapy prior to a formal approval from U.S. regulators. Why are you stalling JT?
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News
InvestorsHub NewsWire

VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM

North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM

Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM

POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM

HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM

Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM

Start posting your company's news
Only $200 per official company press release!